Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2016

01-05-2016 | Breast Oncology

Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer

Authors: Sylvia A. Reyes, MD, Tari A. King, MD, FACS, Kezhen Fei, MS, Rebeca Franco, MPH, Nina A. Bickell, MD, MPH

Published in: Annals of Surgical Oncology | Issue 5/2016

Login to get access

Abstract

Background

Despite the survival benefit associated with adjuvant chemotherapy in early-stage breast cancer, many do not complete treatment. This study identified factors associated with noncompletion of adjuvant chemotherapy among a select population of women with early-stage breast cancer.

Methods

The study sample was obtained from a multicenter study designed to evaluate patient-assistance program usage among early-stage breast cancer patients requiring adjuvant therapy. In this study, 333 patients with stages I and II breast cancer undergoing surgery from October 2006 to September 2009 completed 6-month follow-up surveys assessing their experiences with care, health status, social support, self-efficacy, and treatment beliefs. In- and outpatient medical records were abstracted to assess treatment completion. Of the 333 patients, 198 initiated adjuvant chemotherapy and formed our study cohort. The study compared patients who did and did not complete adjuvant chemotherapy.

Results

The median patient age was 53 years (range 28–86 years). According to self-identification, 41 % of the patients were non-Hispanic white and 21 % were black. A total of 13 patients (7 %) did not complete adjuvant chemotherapy. In the bivariate analysis, the patients not completing chemotherapy were more likely to be black and unmarried women with low emotional social support and a poor body image after treatment. In the multivariate analysis, black race [odds ratio (OR) 5.62; 95 % confidence interval (CI) 1.63–20.36] and poor body image (OR 9.75; 95 % CI 2.12–95.95) were independently associated with noncompletion of chemotherapy.

Conclusions

Overall chemotherapy noncompletion rates were low among women exposed to patient-assistance programs. However, poor body image and black race were independent predictors of uncompleted chemotherapy. The true impact of race in this group may result from social factors that occur more often among black women, including poor social support.
Appendix
Available only for authorised users
Literature
2.
go back to reference Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
3.
go back to reference Early Breast Cancer Trialists’ Collaborative G, Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29–40. Early Breast Cancer Trialists’ Collaborative G, Clarke M, Coates AS, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008;371:29–40.
4.
go back to reference Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44.
5.
go back to reference Ruddy KJ, Pitcher BN, Archer LE, et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol. 2012;23:3075–81.CrossRefPubMedPubMedCentral Ruddy KJ, Pitcher BN, Archer LE, et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol. 2012;23:3075–81.CrossRefPubMedPubMedCentral
6.
go back to reference Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30:419.CrossRefPubMed Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30:419.CrossRefPubMed
7.
go back to reference Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27:2157–62.CrossRefPubMedPubMedCentral Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009;27:2157–62.CrossRefPubMedPubMedCentral
8.
go back to reference Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol.2005;23:6639–46.CrossRefPubMed Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol.2005;23:6639–46.CrossRefPubMed
9.
go back to reference Lipscomb J, Gillespie TW, Goodman M, et al. Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat. 2012;133:285–96.CrossRefPubMedPubMedCentral Lipscomb J, Gillespie TW, Goodman M, et al. Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat. 2012;133:285–96.CrossRefPubMedPubMedCentral
10.
go back to reference Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol. 2009;27:5160–7.CrossRefPubMedPubMedCentral Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol. 2009;27:5160–7.CrossRefPubMedPubMedCentral
11.
go back to reference Wells JS, Strickland OL, Dalton JA, Freeman S. Adherence to intravenous chemotherapy in African American and white women with early-stage breast cancer. Cancer Nurs. 2015;38:89–98.CrossRefPubMedPubMedCentral Wells JS, Strickland OL, Dalton JA, Freeman S. Adherence to intravenous chemotherapy in African American and white women with early-stage breast cancer. Cancer Nurs. 2015;38:89–98.CrossRefPubMedPubMedCentral
12.
go back to reference Bickell NA, Geduld AN, Joseph KA, et al. Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer? J Oncol Pract. 2014;10:48–54.CrossRefPubMed Bickell NA, Geduld AN, Joseph KA, et al. Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer? J Oncol Pract. 2014;10:48–54.CrossRefPubMed
13.
go back to reference Bickell NA, Aufses AH Jr, Chassin M. Engaging clinicians in a quality improvement strategy for early-stage breast cancer treatment. Qual Manage Health Care. 1998;6:63–8.CrossRef Bickell NA, Aufses AH Jr, Chassin M. Engaging clinicians in a quality improvement strategy for early-stage breast cancer treatment. Qual Manage Health Care. 1998;6:63–8.CrossRef
14.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
15.
go back to reference Strogatz DS, Croft JB, James SA, et al. Social support, stress, and blood pressure in black adults. Epidemiology. 1997;8:482–7.CrossRefPubMed Strogatz DS, Croft JB, James SA, et al. Social support, stress, and blood pressure in black adults. Epidemiology. 1997;8:482–7.CrossRefPubMed
16.
go back to reference Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
17.
go back to reference University of California Los Angeles. SAS Code to Score the SF-12 Version 2.0 (computer program). University of California Los Angeles, Los Angeles, CA, 2004. University of California Los Angeles. SAS Code to Score the SF-12 Version 2.0 (computer program). University of California Los Angeles, Los Angeles, CA, 2004.
18.
go back to reference Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med. 2002;162:1985–93.CrossRefPubMed Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med. 2002;162:1985–93.CrossRefPubMed
19.
go back to reference Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522–7.CrossRefPubMed Griggs JJ, Culakova E, Sorbero ME, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;25:2522–7.CrossRefPubMed
20.
go back to reference Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C. Cost of breast cancer treatment in Medicaid: implications for state programs providing coverage for low-income women. Med Care. 2011;49:89–95.CrossRefPubMed Subramanian S, Trogdon J, Ekwueme DU, Gardner JG, Whitmire JT, Rao C. Cost of breast cancer treatment in Medicaid: implications for state programs providing coverage for low-income women. Med Care. 2011;49:89–95.CrossRefPubMed
21.
go back to reference Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 2005;104:2054–62.CrossRefPubMed Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 2005;104:2054–62.CrossRefPubMed
22.
go back to reference Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6:182–7.CrossRefPubMed Guidry JJ, Aday LA, Zhang D, Winn RJ. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6:182–7.CrossRefPubMed
23.
go back to reference Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer. 2010;116:3493–504.CrossRefPubMedPubMedCentral Weaver KE, Rowland JH, Bellizzi KM, Aziz NM. Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States. Cancer. 2010;116:3493–504.CrossRefPubMedPubMedCentral
24.
go back to reference Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 2007;13:581–7.CrossRefPubMed Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 2007;13:581–7.CrossRefPubMed
Metadata
Title
Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer
Authors
Sylvia A. Reyes, MD
Tari A. King, MD, FACS
Kezhen Fei, MS
Rebeca Franco, MPH
Nina A. Bickell, MD, MPH
Publication date
01-05-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-5039-5

Other articles of this Issue 5/2016

Annals of Surgical Oncology 5/2016 Go to the issue